Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGLENASDAQ:CYCNNASDAQ:EQNASDAQ:LSDI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCYCNCyclerion Therapeutics$3.24-1.2%$2.79$1.27▼$9.47$10.40M1.671.31 million shs24,118 shsEQEquillium$0.39-0.1%$0.55$0.34▼$1.66$13.93M2.06356,875 shs50,760 shsLSDILucy Scientific Discovery$0.03$0.44▼$12.80$907K1.41640,390 shs314,500 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%0.00%CYCNCyclerion Therapeutics-1.22%+9.09%+26.56%0.00%+2.86%EQEquillium-0.89%-2.55%-18.58%-56.13%-74.51%LSDILucy Scientific Discovery0.00%0.00%0.00%0.00%-29.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACYCNCyclerion Therapeutics1.7887 of 5 stars0.03.00.00.03.83.30.6EQEquillium2.6532 of 5 stars3.25.00.00.01.91.70.6LSDILucy Scientific DiscoveryN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics 0.00N/AN/AN/ACYCNCyclerion Therapeutics 0.00N/AN/AN/AEQEquillium 2.33Hold$3.00669.23% UpsideLSDILucy Scientific Discovery 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LSDI, CYCN, EQ, and AGLE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00CYCNCyclerion Therapeutics$2M5.20N/AN/A$4.62 per share0.70EQEquillium$41.10M0.34N/AN/A$0.64 per share0.61LSDILucy Scientific Discovery$16.73K0.00N/AN/A$2.86 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ACYCNCyclerion Therapeutics-$5.26M-$1.22N/A∞N/AN/A-55.32%-48.35%5/13/2025 (Estimated)EQEquillium-$13.34M-$0.23N/AN/AN/A-10.05%-20.68%-10.77%N/ALSDILucy Scientific Discovery-$8.99M-$7.00N/AN/AN/AN/A-294.74%-137.65%N/ALatest LSDI, CYCN, EQ, and AGLE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 million3/4/2025Q4 2024CYCNCyclerion TherapeuticsN/A$0.22N/A$0.22N/A$1.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/ALSDILucy Scientific DiscoveryN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59CYCNCyclerion TherapeuticsN/A5.075.07EQEquilliumN/A3.043.04LSDILucy Scientific DiscoveryN/A0.380.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ACYCNCyclerion Therapeutics75.62%EQEquillium27.05%LSDILucy Scientific Discovery72.61%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%CYCNCyclerion Therapeutics36.10%EQEquillium31.60%LSDILucy Scientific DiscoveryN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableCYCNCyclerion Therapeutics303.21 million1.73 millionNo DataEQEquillium4035.72 million24.70 millionNot OptionableLSDILucy Scientific Discovery21.77 millionN/ANot OptionableLSDI, CYCN, EQ, and AGLE HeadlinesRecent News About These Companies50 years after her discovery, Lucy's skeleton still shapes paleoanthropologyNovember 24, 2024 | wuwm.comAfter 50 Years, Scientists Still Love LucyNovember 24, 2024 | smithsonianmag.comHow Discovery of Lucy Skeleton Shaped Our Understanding of Human EvolutionNovember 23, 2024 | newsweek.comLucy’s LegacyNovember 22, 2024 | washingtonpost.comAncient human ancestor Lucy was not alone — she lived alongside at least 4 other proto-human species, emerging research suggestsNovember 22, 2024 | msn.com50 Years Of Science With Lucy, Our Famous Early AncestorNovember 22, 2024 | sciencefriday.comHuman ancestor Lucy still has secrets 50 years after discoveryNovember 21, 2024 | phys.orgFifty years after the discovery of Lucy, it’s time to ‘decolonise paleoanthropology’ says leading Ethiopian fossil expert – podcastNovember 21, 2024 | theconversation.comHow does a fossil become a superstar? Just ask Lucy.November 14, 2024 | sciencenews.orgOur ancestor Lucy may have used tools more than 3 million years agoNovember 13, 2024 | msn.comThe Lucy Fossil’s Extraordinary Journey to Becoming an Icon of Human EvolutionNovember 11, 2024 | scientificamerican.comBritish nurse Lucy Letby loses bid to appeal single attempted murder convictionOctober 25, 2024 | msn.comTMT:USD Turkmenistan Manat / US DollarOctober 19, 2024 | seekingalpha.comLucy Turns 50, and Dark Energy Gets More MysteriousOctober 15, 2024 | scientificamerican.comLucy Scientific Discovery Inc Unit (LSDIF)September 12, 2024 | investing.comKS2 Science: Scientists and their discoveriesAugust 27, 2024 | bbc.co.ukLucy NotarantonioAugust 23, 2024 | newsweek.comDonald Johanson: Unearthing Lucy changed my life and the worldAugust 3, 2024 | msn.comNew discovery challenges existing theories on how celestial bodies are formedMay 29, 2024 | courthousenews.comLucy Scientific Discovery Inc. Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)May 28, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBuffett's Top 5 Stock Holdings Ahead of Next 13F FilingBy Ryan Hasson | May 2, 2025View Buffett's Top 5 Stock Holdings Ahead of Next 13F FilingHow to Invest in Micro-Cap Stocks Like a ProBy Dan Schmidt | April 22, 2025View How to Invest in Micro-Cap Stocks Like a ProStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendAmerican Express: Affluent Customers Don’t Leave Home Without It By Jea Yu | April 26, 2025View American Express: Affluent Customers Don’t Leave Home Without It 3 Stocks Just Announced Intentions to Buyback Near 10% of SharesBy Leo Miller | April 28, 2025View 3 Stocks Just Announced Intentions to Buyback Near 10% of SharesLSDI, CYCN, EQ, and AGLE Company DescriptionsAeglea BioTherapeutics NASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Cyclerion Therapeutics NASDAQ:CYCN$3.24 -0.04 (-1.22%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$3.14 -0.10 (-2.93%) As of 05/12/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Equillium NASDAQ:EQ$0.39 0.00 (-0.13%) Closing price 05/12/2025 03:43 PM EasternExtended Trading$0.40 +0.01 (+2.82%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Lucy Scientific Discovery NASDAQ:LSDILucy Scientific Discovery Inc., an early stage psychotropics contract manufacturing company, engaged in the research, manufacturing, and commercialization of psychedelic products. The company offers biological raw materials, active pharmaceutical ingredients (APIs), and finished biopharmaceutical products. It also develops and produces highly controlled agricultural grow environments for plant manufacturing and replication applications. The company was formerly known as Hollyweed North Cannabis Inc. and changed its name to Lucy Scientific Discovery Inc. in May 2021. Lucy Scientific Discovery Inc. was incorporated in 2017 and is headquartered in Victoria, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
